GVR Report cover In-vitro Diagnostics Enzymes Market Size, Share & Trends Report

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme Type (Polymerase & Transcriptase, Proteases), By Disease Type, By Technology Type, By End-use, By Region, And Segment Forecasts, 2020 - 2027

  • Report ID: GVR-4-68039-246-6
  • Number of Pages: 199
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2018
  • Industry: Healthcare

Report Overview

The global in-vitro diagnostics enzymes market size was valued at USD 706.97 million in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 8.97% from 2020 to 2027. Enzymes are adopted in the diagnosis of various metabolic disorders owing to their remarkable catalytic properties. Several research studies have represented the clinical application of enzymes, such as alanine transaminase, acid phosphatase, creatine kinase, aspartate transaminase, lactate dehydrogenase, and gelatinase-B. These enzymes are preferred biomarkers in several disease conditions, including myocardial infarction, liver disease, schizophrenia, renal disease, rheumatoid arthritis, and cancer.

Canada IVD enzymes market size, by enzyme type, 2016 - 2027 (USD Million)

Various molecular biology techniques are continuously gaining popularity as in-vitro diagnostics (IVD) for the detection and prevention of several diseases. Among these techniques, the polymerase chain reaction (PCR) had a greater impact on the practices involved in the molecular biology field. PCR implements a thermostable polymerase to produce multiple copies of a specific nucleic acid region rapidly and exponentially. Taq polymerase, reverse transcriptase enzyme, and thermostable DNA polymerase are the commonly used enzymes during PCR amplification cycles.

The utility of enzymes for the diagnosis of COVID-19 has spurred the market growth. A wide range of commercial COVID-19 tests is available in the marketplace. Some of the tests either detect the SARS-CoV-2 viral RNA using the nucleic acid hybridization-related strategies or PCR technique while others are serological and immunological assays that detect the antibodies produced in response to the virus.

The PCR method is highly accepted to test the presence of the SARS-CoV-2 virus. This method uses a DNA-copying enzyme, Taq DNA polymerase, which remains active at high temperatures. Along with this, reverse transcriptase is used to copy the RNA of the virus in the DNA for further amplifications. Creative Enzymes and BioVendor are key companies that offer enzymes for the diagnosis of COVID-19.

Enzyme Type Insights

Polymerase and transcriptase accounted for the largest revenue share of 29.5% in 2019 and are anticipated to witness the fastest growth during the forecast period. This is attributed to their wide applications in molecular diagnostic assays. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the segment growth.

The proteases segment is expected to witness significant growth over the forecast period. Proteases are expected to gain traction in the common molecular biology procedures. The application of heat-labile protease is used to digest the heat-stable molecular biology enzymes, such as PvuII and Taq Polymerase, which further inactivates due to a mild heat treatment.

This indicates the major benefit of protease in instances where further chemical reactions can be completed without the requirement of an intermediate purification stage; therefore, it reduces product loss and saves time. This benefit of protease makes it an important diagnostic enzyme to be used in IVD procedures.

The use of proteases in the oncology disease type is expected to witness significant growth throughout the forecast period with the rising cases of cancer globally and the expansion of IVD techniques, such as In Situ Hybridization (ISH) and Next-Generation Sequencing (NGS), in the field of oncology.

Disease Type Insights

Infectious disease accounted for the largest revenue share of 27.3% in 2019. The wide applicability of PCR technology in infectious disease diagnosis has led to early diagnosis and treatment. Organisms that are difficult to be detected can now be identified with better precision and sensitivity. The application of PCR in infectious disease diagnosis includes detection of tuberculosis, streptococcal pharyngitis, atypical pneumonia, ulcerative urogenital infections, and several persistent infections.

The Thermus thermophilus DNA polymerase gene expressed in Escherichia coli allows an efficient reverse transcriptase activity for the detection of cellular mRNA expression in a single step. Moreover, an IgM antibody capture ELISA (MAC-ELISA) is a proven technology for dengue diagnosis during the early convalescent or late acute phase of the infection. Platelia Dengue NS1 antigen-capture ELISA kits and Panbio Dengue Duo IgG and IgM Rapid Cassette test kits are some of the enzyme-based kits for the diagnosis of infectious diseases.

The oncology segment is expected to expand at the fastest CAGR throughout the forecast period. Large-scale adoption of ISH methods as well as the development of high-throughput technologies, such as next-generation DNA sequencing and comparative genomic hybridization, for the diagnosis of human tumors drive the usage of diagnostic enzymes in the oncology segment.

Technology Type Insights

Histology assays dominated the IVD enzymes market with a revenue share of 44.9% in 2019owing to the advantages offered by the technique in the analysis of tissue samples for diagnostic purposes. Moreover, histopathology is quick, with little or no risk to patients, and helps clinicians analyze the internal architecture of tissues and cells.

Molecular diagnostics is preferred over serology for the diagnosis of infectious diseases as this technique is highly sensitive and offers detection of disease-causing agents, allowing early detection of several disorders. The molecular diagnostics segment is expected to witness the fastest growth over the forecast period. Moreover, enzymes are crucial to multiple steps in molecular diagnostic assays, such as NGS library and sample preparation. They provide shortcuts for difficult or slow reactions and enable repair, modification, and amplification of nucleic acids for a wide range of applications.

Enzymes form an essential component of the clinical chemistry diagnostic assays owing to the specificity and speed offered by enzymes. Enzyme specificity is used either for the removal of interferents in another reaction or for the measurement of a substrate in an assay. Enzymes are also used to measure activators, inhibitors, or cofactors. In addition, the catalytic activity of enzymes makes them ideal for use as labels in immunoassay techniques. Thus, key players, such as BBI Solutions, offer a wide range of enzymes for clinical chemistry use.

End-use Insights

The hospitals and diagnostic laboratories segment dominated the market with a share of 39.8% in 2019. The usage of IVD assays in hospitals has increased over the years. In several hospitals and clinics, the physicians are switching to histopathology and molecular diagnostics from conventional testing procedures. The long turnover time associated with the conventional processes is boosting the adoption rate of histopathology-based tests as these aid in reducing the timelines.

The academic labs segment is expected to expand at the fastest CAGR from 2020 to 2027. An increase in the application of NGS and PCR technologies in academic and institutional projects drives the adoption rate of diagnostic enzymes used during the IVD procedures conducted in these settings.

Global IVD enzymes market share, by end-use, 2019 (%)

For instance, researchers at the UNC Medical Center Microbiology and Molecular Microbiology Laboratories, the U.S., explored the usage of NGS technology for accurate COVID-19 diagnosis in March 2020. The use of this technology helped scientists in the identification of the mutations and gain insights related to the genomic code of COVID-19 causing virus. This application of NGS drives the utilization of enzymes used in library preparation, such as T4 polynucleotide kinas, ligase, DNA polymerase, and reverse transcriptase.

Regional Insights

North America occupied the largest share of 41.76% in 2019 owing to the high demand for IVD enzymes and the increasing prevalence of infectious disorders in the region. To combat the ongoing COVID-19 pandemic, the FDA has issued emergency use authorizations for in-vitro COVID-19 laboratory-developed tests.

In addition, most of these emergency use authorizations are Enzyme-Linked Immunosorbent Assay (ELISA) and Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based tests for the detection of SARS-CoV-2. Owing to the high usability of enzymes during RT-PCR, the development of such tests is expected to generate revenue in the North American market.

Asia Pacific is anticipated to be the fastest-growing regional market over the forecast period due to the improvements in healthcare infrastructure, the introduction of insurance policies allowing favorable reimbursements, and increasing prevalence of cancer and HIV/AIDS, leading to increased demand for diagnostic tests. China holds a significant position in the Asia Pacific market due to the presence of several suppliers of enzymes.

Key Companies & Market Share Insights

Key companies are making continuous efforts to fulfill the demand for enzymes utilized during diagnostic procedures for clinical disorders, especially COVID-19. For instance, in May 2020, Richcore Lifesciences, an Indian company, along with the Indian Institute of Science Education and Research at Pune and Chandigarh and the Indian Institute of Science, Bengaluru, has produced and optimized Reverse Transcriptase and Taq Polymerase, two key enzymes, for the RT-PCR diagnostic kits.

The company is currently offering these enzyme samples to test kit manufacturers to approve the consistency and stability of enzymes. Once approved, the company would be able to mass-produce these enzymes for millions of certified testing kits in India. Such initiatives undertaken by the companies drive large-scale production of enzymes to address the urgent need for testing kits for COVID-19 diagnosis. Some prominent players in the global in-vitro diagnostics enzymes market include:

  • Merck KGaA

  • Codexis, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Amano Enzyme Inc.

  • Advanced Enzymes Technologies Ltd.

  • Biocatalysts Ltd.

  • Amicogen

  • Dyadic International

  • BBI Solutions

  • Affymetrix

  • American Laboratories

In-vitro Diagnostics Enzymes Market Report Scope

Report Attribute


Market size value in 2020

USD 774.78 million

Revenue forecast in 2027

USD 1,405.56 million

Growth Rate

CAGR of 8.97% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Enzyme type, disease type, technology type, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Brazil; Mexico; South Africa

Key companies profiled

Merck KGaA; Codexis, Inc.; F. Hoffmann-La Roche Ltd.; Amano Enzyme Inc.; Advanced Enzymes Technologies Ltd.; Biocatalysts Ltd.; Amicogen; Dyadic International; BBI Solutions; Affymetrix; American Laboratories

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global in-vitro diagnostics enzymes market report on the basis of enzyme type, disease type, technology type, end-use, and region:

  • Enzyme Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Proteases

      • By Disease Type

        • Infectious disease

        • Diabetes

        • Oncology

        • Cardiology

        • Nephrology

        • Autoimmune diseases

        • Others

      • By Technology Use

        • Histology Assays

        • Molecular Diagnostics

        • PCR Assays

        • NGS Assays

        • Others

        • Clinical Chemistry

      • By Physical Form

        • Powder

        • Liquid

        • By Type

        • Natural

        • Recombinant

      • By End-use

        • Pharma & Biotech

        • Hospital & Diagnostic Labs

        • CROs

        • Academic Labs

    • Polymerase & Transcriptase

    • Ribonuclease

    • Others

  • Disease Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Infectious disease

      • COVID-19 Testing

      • Hepatitis

      • HIV

      • Others

    • Diabetes

    • Oncology

    • Cardiology

    • Nephrology

    • Autoimmune diseases

    • Others

  • Technology Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Histology Assays

    • Molecular Diagnostics

      • PCR Assays

      • NGS Assays

      • Others

    • Clinical Chemistry

  • End-use Outlook (Revenue, USD Million, 2016 - 2027)

    • Pharma & Biotech

    • Hospital & Diagnostic Labs

    • Contract Research Organizations (CROs)

    • Academic Labs

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East and Africa (MEA)

      • South Africa

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon